LB2305 - Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial

Presenting Author(s)

• 

  Abdel G. Babiker, PhD

  Professor
  University College London
  London, England, United Kingdom

  Disclosure: Disclosure(s): No financial relationships to disclose

  Slides

Co-Author(s)

• 

  Jens Lundgren, MD DMSc

  Professor
  Rigshospitalet, University of Copenhagen
  Copenhagen, Hovedstaden, Denmark

  Disclosure: Disclosure(s): No financial relationships to disclose
• SS

  Shweta Sharma, MS

  University of Minnesota
  Minneapolis, Minnesota, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• BG

  Birgit Grund, Ph.D.

  Professor
  University of Minnesota
  Minneapolis, Minnesota, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• AP

  Andrew Phillips, PhD

  UCL
  London, England, United Kingdom

  Disclosure: Disclosure(s): No financial relationships to disclose
• VK

  Virginia L. Kan, MD

  Chief
  VA Medical Center
  Washington, District of Columbia, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• 

  Gail Matthews, MBChB, PhD

  Associate Professor
  Kirby Institute, UNSW
  Sydney, New South Wales, Australia

  Disclosure: Disclosure(s): Abbvie Inc: Grant/Research Support (); Astra Zeneca: Advisor/Consultant (); Gilead Sciences: Advisor/Consultant (), Grant/Research Support (); Janssen: Advisor/Consultant (), Grant/Research Support (); ViiV Healthcare: Advisor/Consultant (), Grant/Research Support ()
• KK

  Karin L. Klingman, MD

  Medical Consultant
  Medical Science and Computing
  Silver Spring, Maryland, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• JN

  James D. Neaton, PhD

  Professor of Biostatistics
  University of Minnesota
  Minneapolis, Minnesota, United States

  Disclosure: Disclosure(s): No financial relationships to disclose